The Influence of Thromboxane Receptor Blockade on Platelet Uptake in Dacron Grafts in Man
Human prosthetic vascular grafts do not sustain a growth of endothelium on the luminal surface and remain thrombogenic indefinitely1. Whilst large diameter aortic grafts develop a thin layer of platelet thrombus as pseudointima, smaller prostheses such as those in the femoro-popliteal position have a thrombosis and occlusion rate approaching 60% at 1 year after implantation2. Platelet inhibitory therapy is established in the prevention of thrombosis but the combination of aspirin plus dipyridamole produces frequent gastro-intestinal side effects. This has been shown in the recent Persantin Aspirin Re-infarction Study3 where 25% of patients had to discontinue aspirin therapy. Thromboxane A2 (TXA2) which is a product of aracidonic acid metabolism, is a powerful stimulator of platelet aggregation4. It is produced by enzymes including cyclo-oxygenase and thromboxane synthetase in platelets and the natural biological opponent of TXA2 is prostocyclin (PGI2).
KeywordsPlacebo Iodine Aspirin Luminal Polytetrafluoroethylene
Unable to display preview. Download preview PDF.
- 1.M. Goldman, H.C. Norcott, R.J. Hawker, Z. Drolc and C.N. McCollum, Platelet accumulation on mature Dacron grafts in man, Br. J. Surg. 69 (Suppl.): 538, (1982).Google Scholar
- 3.Paris Research group, Persantin and aspirin in coronary heart disease, Circulation, 62: 449, (1980).Google Scholar
- 7.D.J. Doyle, C.N. Chesterman, J.F. Casle and F.J. Morgan, Platelet concentrations of platelet specific proteins correlated with platelet survival, Thromb. and Haemost. 42: 329 (1979).Google Scholar
- 9.M. Goldman, C. Hall, R.J. Hawker and C.N. McCollum, Dazoxiben 147 examined for platelet inhibitory effect in an artificial circulation, Br. J. Pharmac. 15:615 (1983).Google Scholar